Observation

CENTESSA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, September 30, 2022

Investors have until November 28, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 28, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • As of the time the complaint was filed, Centessas ADS price continues to trade significantly below the $20.00 per ADS Offering price, damaging investors.

INVESTOR ALERT: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead the Centessa Class Action Lawsuit - CNTA

Retrieved on: 
Thursday, September 29, 2022

), the Centessa class action lawsuit charges Centessa as well as certain of its top executive officers and directors with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934.

Key Points: 
  • ), the Centessa class action lawsuit charges Centessa as well as certain of its top executive officers and directors with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the Centessa class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Centessa class action lawsuit.
  • An investors ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Centessa class action lawsuit.

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Centessa Pharmaceuticals plc (CNTA)

Retrieved on: 
Thursday, September 29, 2022

The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased Centessa Pharmaceuticals plc (NASDAQ: CNTA) American Depository Shares (ADS) pursuant to the Company's May 28, 2021, initial public offering ("IPO") and/or between May 28, 2021 and June 1, 2022.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased Centessa Pharmaceuticals plc (NASDAQ: CNTA) American Depository Shares (ADS) pursuant to the Company's May 28, 2021, initial public offering ("IPO") and/or between May 28, 2021 and June 1, 2022.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • If you would like more information about Centessa Pharmaceuticals plc's misconduct, click here .
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

CENTESSA PHARMACEUTICALS PLC (NASDAQ: CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals plc (NASDAQ: CNTA)

Retrieved on: 
Thursday, September 29, 2022

NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired: (a) Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021 (the “IPO” or “Offering”); and/or (b) Centessa securities between May 28, 2021 and June 1, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Centessa Pharmaceuticals plc Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • Plaintiff alleges that Defendants made materially false and misleading statements in the Offering Documents and throughout the Class Period.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Global Microservices in Healthcare Market Report 2022: Rising Need for Digitization across the Healthcare Sector Bolsters Growth

Retrieved on: 
Thursday, September 29, 2022

The Global Microservices in Healthcare Market is segmented based on Component, Deployment, End-user, and Geography.

Key Points: 
  • The Global Microservices in Healthcare Market is segmented based on Component, Deployment, End-user, and Geography.
  • By End-user, the market is classified into Healthcare Providers, Healthcare Payers, Life Science Organizations, and Clinical Laboratories.
  • The report presents a detailed Ansoff matrix analysis for the Global Microservices in Healthcare Market.
  • The report offers a comprehensive evaluation of the Global Microservices in Healthcare Market.

Global Fetal Bovine Serum Market Report 2022: Rising Demand for Fetal Bovine Serum for Research Studies Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

The Global Fetal Bovine Serum Market is segmented based on Product, Application, End-user, and Geography.

Key Points: 
  • The Global Fetal Bovine Serum Market is segmented based on Product, Application, End-user, and Geography.
  • By Product, the market is classified into Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted, Stem Cell.
  • The report presents a detailed Ansoff matrix analysis for the Global Fetal Bovine Serum Market.
  • The report offers a comprehensive evaluation of the Global Fetal Bovine Serum Market.

Global Vitamin D Testing Market (2022 to 2027) - Featuring Abbott Laboratories, Biokit, bioMerieux and Danaher Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

The Global Vitamin D Testing Market is estimated to be worth USD 632 million in 2022, and is expected to reach USD 837.81 million by 2027, growing at a CAGR of 5.8%.

Key Points: 
  • The Global Vitamin D Testing Market is estimated to be worth USD 632 million in 2022, and is expected to reach USD 837.81 million by 2027, growing at a CAGR of 5.8%.
  • The report presents a detailed Ansoff matrix analysis for the Global Vitamin D Testing Market.
  • The Global Vitamin D Testing Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Vitamin D Testing Market.

The Worldwide Microdermabrasion Devices Industry is Expected to Reach $739 Million by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

The Global Microdermabrasion Devices Market is estimated to be worth USD 478.3 million in 2022, and is expected to reach USD 739.31 million by 2027, growing at a CAGR of 9.1%.

Key Points: 
  • The Global Microdermabrasion Devices Market is estimated to be worth USD 478.3 million in 2022, and is expected to reach USD 739.31 million by 2027, growing at a CAGR of 9.1%.
  • These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.
  • The report presents a detailed Ansoff matrix analysis for the Global Microdermabrasion Devices Market.
  • Based on the SWOT analysis conducted on the industry and industry players, suitable strategies have been devised for market growth.

Insights on the Ultra-low Temperature Freezers Global Market to 2027 - Rise In R&D Activities To Introduce New Drug Compounds Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

The report presents a detailed Ansoff matrix analysis for the Global Ultra-low Temperature Freezers Market.

Key Points: 
  • The report presents a detailed Ansoff matrix analysis for the Global Ultra-low Temperature Freezers Market.
  • The Global Ultra-low Temperature Freezers Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Ultra-low Temperature Freezers Market.
  • The Global Ultra-low Temperature Freezers Market is segmented based on Product, Cooling, Application, Technology, Defrosting Type, End-user, and Geography.

Pomerantz Law Firm Announces the Filing of a Class Action Against Centessa Pharmaceuticals plc and Certain Officers and Directors – CNTA

Retrieved on: 
Thursday, September 29, 2022

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.